Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) — Capital Reinvestment Ratio
Latest as of December 2024:
0.82x
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has a Capital Reinvestment Ratio of 0.82x as of December 2024, meaning it reinvests 1% of its operating cash flow (CN¥102.67 Million) in capital expenditures (CN¥83.91 Million). See 301089 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.82x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥102.67 Million
CNY
Capital Expenditures
CN¥83.91 Million
CNY
Data as of
Dec 2024
Most recent filing
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Capital Reinvestment Ratio (2019–2024)
This chart tracks Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2024)
Year-by-year Capital Reinvestment Ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2024. For live market cap and broader valuation context, see 301089 market cap overview.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.82x | CN¥102.67 Million | CN¥83.91 Million | ▼ -88.1% |
| 2023 | 6.87x | CN¥26.95 Million | CN¥185.22 Million | ▲ +1145.5% |
| 2022 | 0.55x | CN¥268.85 Million | CN¥148.33 Million | ▼ -71.5% |
| 2021 | 1.94x | CN¥58.19 Million | CN¥112.73 Million | ▲ +213.6% |
| 2020 | 0.62x | CN¥120.00 Million | CN¥74.12 Million | ▼ -30.0% |
| 2019 | 0.88x | CN¥86.38 Million | CN¥76.20 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow